Provided by Tiger Trade Technology Pte. Ltd.

VanEck Healthcare TruSector ETF

29.00
+0.00010.00%
Post-market: 28.92-0.0754-0.26%16:10 EDT
Volume:1K
Turnover:33.93K
Market Cap:579.91K
PE:- -
High:29.00
Open:28.98
Low:28.92
Close:29.00
52wk High:30.68
52wk Low:24.78
Shares:20.00K
Float Shares:20.00K
Volume Ratio:1.93
T/O Rate:5.86%
Dividend:0.09
Dividend Rate:0.30%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson & Johnson Says Phase 3 Trial Shows Caplyta Cuts Bipolar I Mania Symptoms by Week 3

Reuters
·
Sep 21

Abbvie and Iambic Announce Collaboration to Accelerate AI-Driven Drug Discovery

THOMSON REUTERS
·
Sep 21

Abbvie - Iambic to Receive Upfront Payment, Milestone Payments, and Tiered Royalties from Collaboration

THOMSON REUTERS
·
Sep 21

Abbvie - Partnership to Accelerate Small Molecule Drug Discovery in Immunology, Neuroscience, Oncology

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Sep 21

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Sep 21

Adarx Pharmaceuticals: IPO Price Expected Between $15 and $17 Per Share

Reuters
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Sep 21

ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO

Dow Jones
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Sep 21

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Drug Developer ADARx Seeks $1.74 Billion Valuation in US IPO

Reuters
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Health Advisory: Avoid Misusing Weight-Loss Medications, Prioritize Evaluation Before Treatment

Deep News
·
Sep 19